CARLSBAD, CA–(Marketwired – July 28, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that it will complete a 1:150 reverse split of its common stock.
As of the opening of trading on July 29, 2015, the Company’s common stock will trade on the OTC Markets Group on a reverse stock split adjusted basis. For a period of approximately 20 days, the ticker symbol of the common stock will be ISCOD. Every 150 shares of ISCO’s issued and outstanding pre-reverse split common stock will be automatically converted into one issued and outstanding share of post-reverse split common stock, with no change in par value per share. Stockholders will receive an additional share of post-reverse split common stock in lieu of any fractional shares.